(Q51579932)

7 April 2018

title

Pharmacokinetic and pharmacodynamic interactions between diltiazem and quinidine. (English)

1 reference

7 April 2018

author name string

Laganière S

1

1 reference

7 April 2018

Davies RF

2

1 reference

7 April 2018

Carignan G

3

1 reference

7 April 2018

Foris K

4

1 reference

7 April 2018

Goernert L

5

1 reference

7 April 2018

Carrier K

6

1 reference

7 April 2018

Pereira C

7

1 reference

7 April 2018

McGilveray I

8

1 reference

7 April 2018

language of work or name

English

0 references

publication date

1 September 1996

1 reference

7 April 2018

Clinical Pharmacology & Therapeutics

published in

1 reference

7 April 2018

volume

60

1 reference

7 April 2018

page(s)

255-264

1 reference

7 April 2018

issue

3

1 reference

7 April 2018

Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990052-1

Alteration of propranolol pharmacokinetics and pharmacodynamics by quinidine in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990052-1

Effect of quinidine on the dextromethorphan O-demethylase activity of microsomal fractions from human liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990052-1

Quinidine: potent inhibition of sparteine and debrisoquine oxidation in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990052-1

Genetically-determined interaction between propafenone and low dose quinidine: role of active metabolites in modulating net drug effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990052-1

The pharmacokinetics and pharmacodynamics of quinidine and 3-hydroxyquinidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990052-1

Population pharmacokinetics of quinidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990052-1

Possible inhibition of hepatic metabolism of quinidine by erythromycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990052-1

Extensive metabolizers of debrisoquine become poor metabolizers during quinidine treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990052-1

Competitive inhibition of sparteine oxidation in human liver by β-adrenoceptor antagonists and other cardiovascular drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990052-1

Quinidine reduces clearance of (+)-propranolol more than (-)-propranolol through marked reduction in 4-hydroxylation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990052-1

Single-dose quinidine treatment inhibits metoprolol oxidation in extensive metabolizers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990052-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990052-1

Inhibition of hepatic microsomal drug metabolism by the calcium channel blockers diltiazem and verapamil.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990052-1

Diltiazem. A reappraisal of its pharmacological properties and therapeutic use.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990052-1

The effect of diltiazem on the disposition of encainide and its active metabolites

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990052-1

Comparison of Verapamil, Diltiazem, and Labetalol on the Bioavailability and Metabolism of Imipramine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990052-1

Catalytic activities of human liver cytochrome P-450 IIIA4 expressed in Saccharomyces cerevisiae

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990052-1

Simultaneous determination of diltiazem and quinidine in human plasma by liquid chromatography

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990052-1

Pharmacokinetics of quinidine related to plasma protein binding in man

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990052-1

The effects of diltiazem on cardiac function in silent ischemia after myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990052-1

Clinical pharmacokinetics of quinidine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990052-1

Pharmacokinetics of diltiazem after intravenous and oral administration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990052-1

Reliability of antiarrhythmic drug plasma concentration monitoring

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990052-1

Pharmacodynamic aspects of intravenous diltiazem administration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2896%2990052-1

10.1016/S0009-9236(96)90052-1

7 January 2021

Identifiers

DOI

1 reference

7 April 2018

PubMed ID

8841148

1 reference

7 April 2018